Vivodyne Appoints Julie O’Shaughnessy as Chief Operating Officer

May 7, 2024 |

3 min read

Vivodyne, a pioneering biotech company that grows and tests on lab-grown human tissues to accelerate therapeutics discovery and development, announced the appointment of Julie O’Shaughnessy as Chief Operating Officer.

PHILADELPHIA--(BUSINESS WIRE)-- Vivodyne, a pioneering biotech company that grows and tests on lab-grown human tissues to accelerate therapeutics discovery and development, today announced the appointment of Julie O’Shaughnessy as Chief Operating Officer. In her new role, Julie will oversee business operations, strategic planning, finance, people operations, and multisite expansion, driving the company’s operational excellence and strategic growth initiatives.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240506648531/en/

Julie O’Shaughnessy, Chief Operating Officer, Vivodyne (Photo credit: Vivodyne)

Prior to joining Vivodyne, Julie served in key leadership roles at Resilience and Amazon Web Services (AWS). At Resilience, she led the foundational operations scale-up of the digital team to numerous North American sites and thousands of workers in under three years. During her tenure at AWS, she founded the Global Sales Cycle Acceleration Operations function to more effectively serve enterprise customers, before moving to lead Global Strategy and Operations for the Startup & VC arm of the business during a hypergrowth period. She started her career in Investment Banking at UBS and Barclays.

“Julie has been instrumental in Vivodyne’s growth and has also been the driving force behind our critical operations and talent acquisition at the highest level — and an incredible part of our team,” said Andrei Georgescu, Ph.D., CEO & Co-Founder of Vivodyne. “Julie is leading essential functions at the intersection of people, finance, and business operations, and her exceptional leadership qualities have been constantly evident since joining. Her expertise and strategic leadership will be transformative as we continue to expand our team, shape our growth strategy, and scale our platform, which uses functional, lifelike, lab-grown human organs for drug discovery and development.”

Julie joined Vivodyne in January 2024 as Vice President of Operations. Bringing 15 years of experience in building and scaling high-performing teams, she is a passionate strategic leader who focuses on building dynamic, inclusive, and collaborative cultures and establishing efficient business architectures. She has led teams responsible for portfolio management, strategic planning, business operations and analytics development, enterprise application deployment, enablement, and change management.

“The mission and innovative technology is what drew me to Vivodyne and I’ve been extremely impressed with what our team has been able to achieve in such a short period — I am very excited to help take Vivodyne to the next level,” said O’Shaughnessy. “I look forward to working alongside our full team to drive rapid advancement in the drug discovery and development landscape, by bringing human data before clinical trials using Vivodyne’s lab-grown human organs.”

Julie is actively involved in various organizations, serving as Vice Chair of the Board at the Ali Forney Center, the largest organization dedicated to supporting homeless LGBTQ+ youth, and as an Executive Committee member for the University of New Hampshire’s Athletics Advisory Board. She is also an avid supporter of melanoma research, having raised over $500,000 through her participation in numerous marathons and many fundraising events.

About Vivodyne

Vivodyne accelerates the successful discovery, design, and development of human therapeutics through the convergence of novel biology, robotics, and AI. The platform enables life sciences companies to massively de-risk drug candidates by testing them against functional, lab-grown human organs and multi-organ systems. Vivodyne conducts preclinical discovery and clinical development campaigns on our proprietary, physiologically realistic organs, enabling the generation of novel therapeutic strategies at an unprecedented scale, speed, and quality. For more information, visit https://vivodyne.com. Follow us @vivodyne.